|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
A/S Ferrosan
Chelsea Therapeutics
Ovatio
|
|
gptkbp:CEO
|
gptkb:Deborah_Dunsire
|
|
gptkbp:country
|
gptkb:Denmark
|
|
gptkbp:focusesOn
|
central nervous system disorders
|
|
gptkbp:foundedBy
|
gptkb:Hans_Lundbeck
|
|
gptkbp:foundedYear
|
1915
|
|
gptkbp:headquartersLocation
|
gptkb:Copenhagen
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
H Lundbeck
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:memberOf
|
gptkb:European_Federation_of_Pharmaceutical_Industries_and_Associations
|
|
gptkbp:netIncome
|
DKK 2.1 billion (2023)
|
|
gptkbp:notableProduct
|
gptkb:Brintellix
gptkb:Cipralex
gptkb:Abilify_Maintena
gptkb:Northera
gptkb:Sabril
Onfi
|
|
gptkbp:numberOfEmployees
|
~5600
|
|
gptkbp:publiclyTraded
|
yes
|
|
gptkbp:researchInterest
|
gptkb:Alzheimer's_disease
gptkb:Parkinson's_disease
gptkb:depression
epilepsy
schizophrenia
migraine
|
|
gptkbp:revenue
|
DKK 18.2 billion (2023)
|
|
gptkbp:servesArea
|
worldwide
|
|
gptkbp:stockExchange
|
gptkb:Nasdaq_Copenhagen
|
|
gptkbp:stockSymbol
|
gptkb:LUN
|
|
gptkbp:subsidiary
|
gptkb:Lundbeck_Foundation
|
|
gptkbp:website
|
https://www.lundbeck.com/
|
|
gptkbp:bfsParent
|
gptkb:Shionogi
|
|
gptkbp:bfsLayer
|
6
|